Stock GOSS GOSSAMER BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
0.7328 USD +1.78% Intraday chart for Gossamer Bio, Inc. +0.18% -19.69%
05-07 Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-06 Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
BU
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Gossamer Bio: Q1 Earnings Snapshot
AQ
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
BU
Gossamer bio announces publication of torrey phase 2 results in the lancet respiratory medicine
AQ
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
BU
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
BU
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
BU
Gossamer Bio: Q4 Earnings Snapshot
AQ
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
BU
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
BU
Gossamer bio announces inducement grant under nasdaq listing rule 5635(4)
AQ
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
BU
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
BU
Gossamer Bio: Q3 Earnings Snapshot
AQ
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
BU
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
BU
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GOSS Stock
  4. News Gossamer Bio, Inc.
  5. Press Releases